XML 38 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
$ in Thousands
3 Months Ended
Sep. 28, 2016
USD ($)
Agreement
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Jul. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenues   $ 27,439 $ 21,303    
Contract liabilities   108,652   $ 111,055  
Collaboration and License agreements | Amgen          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Agreement date Sep. 28, 2016        
Number of agreements | Agreement 2        
Cash received as due under collaboration agreement $ 35,000        
License Collaboration And Stock Purchase Agreement | Amgen          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from the issuance of common stock 21,500        
Olpasiran and ARO-AMG1 Agreement | Amgen          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payments $ 30,000       $ 20,000
Revenues   0 $ 0    
Contract liabilities   0      
Contract assets   0      
Olpasiran Agreement | Amgen | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Additional remaining development regulatory and sales milestones payments   $ 400,000